Insight Molecular Diagnostics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham reiterated a Buy rating on the stock and has a $9.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Matson has given his Buy rating due to a combination of factors that highlight Insight Molecular Diagnostics’s promising trajectory. The company is making significant strides with its GraftAssureIQ test, which is already performing well in the research use only phase. Furthermore, Insight Molecular Diagnostics is on track to launch its GraftAssureDx Kidney kitted test by mid-2026, contingent on FDA clearance, and has already signed on 19 transplant centers, with plans to reach at least 20 by the end of 2025.
Additionally, the initiation of a large 5,000 patient registry using GraftAssureCore could potentially boost revenue streams. Despite a cash burn that might slightly exceed their target, the company ended the third quarter of 2025 with a solid cash position of approximately $20.2 million. These developments, coupled with the progress in their clinical trials, have led to an increased price target from $4.25 to $9.00, reinforcing the Buy recommendation.
According to TipRanks, Matson is an analyst with an average return of -2.5% and a 39.96% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific, Penumbra, and TransMedics Group.